Statistiche di base
| LEI | 254900K1GAHHPGQGTS83 |
| CIK | 1531048 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inari Medical, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39293 Inari Medical, Inc. (Exact name of registrant as specified in its |
|
| February 19, 2025 |
AMENDED AND RESTATED INARI MEDICAL, INC. ARTICLE I. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INARI MEDICAL, INC. ARTICLE I. OFFICES Section 1. Registered Office. The registered office of Inari Medical, Inc., (the “Corporation”) in the State of Delaware shall be located at such location as stated in the Certificate of Incorporation of the Corporation, which may be changed from time to time. Section 2. Special Meetings. The Corporation may also hav |
|
| February 19, 2025 |
As filed with the Securities and Exchange Commission on February 19, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 19, 2025 Registration No. |
|
| February 19, 2025 |
As filed with the Securities and Exchange Commission on February 19, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 19, 2025 Registration No. |
|
| February 19, 2025 |
As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No. |
|
| February 19, 2025 |
Exhibit (a)(5)(C) February 19, 2025 Press release Stryker completes acquisition of Inari Medical, Inc. |
|
| February 19, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION INARI MEDICAL, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INARI MEDICAL, INC. FIRST: The name of the corporation (which is hereinafter referred to as the “Corporation”) is Inari Medical, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is The Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle, Delaware 19801. |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Name of Filing Person (Offeror)) A wholly owned subsidiary of Stryker Corporation (Name of Filing Person (Parent of Offe |
|
| February 19, 2025 |
As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No. |
|
| February 19, 2025 |
As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No. |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 19, 2025 |
As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number |
|
| February 14, 2025 |
Stryker Acquisition: Purchase of Inari Shares Exhibit (a)(5)(K) Stryker Acquisition: Purchase of Inari Shares FAQs 1. What will happen to my stock at the close of the acquisition? See below chart for the different equity vehicles and how they will be processed. Owned or Purchased Shares (i.e. shares previously received upon settlement of equity awards or purchased under the ESPP) Unvested RSUs and PSUs will be cancelled in exchange for cash U |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number |
|
| February 6, 2025 |
Exhibit (a)(5)(J) Team Purple – We are writing to address some questions we have received related to the pending acquisition of Inari by Stryker, which was announced on January 6, 2025. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Name of Filing Person (Offeror)) A wholly owned subsidiary of Stryker Corporation (Name of Filing Person (Parent of Offe |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number |
|
| January 17, 2025 |
Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Inari Medical, Inc. |
|
| January 17, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number |
|
| January 17, 2025 |
Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| January 17, 2025 |
Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Inari Medical, Inc. |
|
| January 17, 2025 |
Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of INARI MEDICAL, INC. |
|
| January 17, 2025 |
Exhibit (e)(3) EXECUTION VERSION CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (this “Agreement”), dated as of December 2, 2024, is by and between Stryker Corporation, a Michigan corporation (“Counterparty”), and Inari Medical, Inc. |
|
| January 17, 2025 |
Exhibit 107 Calculation of Filing Fee Table SC TO -T (Form Type) INARI MEDICAL, INC. |
|
| January 17, 2025 |
CLEAN TEAM CONFIDENTIALITY AGREEMENT Exhibit (d)(4) ATTORNEY WORK PRODUCT PRIVILEGED AND CONFIDENTIAL CLEAN TEAM CONFIDENTIALITY AGREEMENT This Clean Team Confidentiality Agreement (the “Agreement”) is entered into this 19th day of December 2024, between Stryker Corporation and all affiliates thereof (“you”, “your” or “Stryker”), and Inari Medical, Inc. |
|
| January 17, 2025 |
Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Inari Medical, Inc. |
|
| January 17, 2025 |
Exhibit (d)(2) EXECUTION VERSION JOINDER This JOINDER TO THE AGREEMENT AND PLAN OF MERGER (this “Joinder”), is made and entered into as of January 7, 2025, by Eagle 1 Merger Sub, Inc. |
|
| January 17, 2025 |
Exhibit (d)(3) EXECUTION VERSION CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (this “Agreement”), dated as of December 2, 2024, is by and between Stryker Corporation, a Michigan corporation (“Counterparty”), and Inari Medical, Inc. |
|
| January 17, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of Inari Medical, Inc. |
|
| January 17, 2025 |
CLEAN TEAM CONFIDENTIALITY AGREEMENT Exhibit (e)(4) CLEAN TEAM CONFIDENTIALITY AGREEMENT This Clean Team Confidentiality Agreement (the “Agreement”) is entered into this 19th day of December 2024, between Stryker Corporation and all affiliates thereof (“you”, “your” or “Stryker”), and Inari Medical, Inc. |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Name of Filing Person (Offeror)) A wholly owned subsidiary of Stryker Corporation (Name of Filing Person (Parent of Offeror)) Common Stock |
|
| January 15, 2025 |
Exhibit 99.2 Dear Valued Partner – On January 6, 2025 we announced that Inari Medical has entered into a definitive agreement to be acquired by Stryker. You can read the press release announcing the transaction linked here. This is an exciting development that will greatly benefit patients, physicians, and hospitals. What will not change is the commitment to our products, clinical trials, physicia |
|
| January 15, 2025 |
Exhibit 99.1 Dear Valued Partner, I am reaching out with some exciting news. Recently, we announced that Inari is being acquired by Stryker. You can read the press release we issued announcing the transaction here. We believe that combining Inari’s world-class VTE treatments with Stryker’s capabilities and global footprint will allow us to build on our momentum, enter new markets and further impac |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) INARI MEDICAL, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number of |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) INARI MEDICAL, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number of |
|
| January 7, 2025 |
EX-99.2 Exhibit 99.2 NARI Transaction Employee FAQ 1. What was announced? • Inari has entered into an agreement to be acquired by Stryker. The press release announcing the transaction can be found on Inari’s investor relations website. • This transaction marks an exciting next chapter of our Ethos of putting patients first, making no small plans and taking care of each other. • Stryker shares our |
|
| January 7, 2025 |
EX-99.1 Exhibit 99.1 Team Purple, Today, we announced that Inari Medical has entered an agreement to be acquired by Stryker. Attached is a copy of the press release announcing the transaction. This marks an exciting new chapter of our Ethos of putting patients first, making no small plans and taking care of each other. Combining Inari’s world-class VTE treatments with Stryker’s capabilities and gl |
|
| January 7, 2025 |
EX-99.1 Exhibit 99.1 January 6, 2025 Press release Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment PORTAGE, Mich. and IRVINE, Calif., USA – January 6, 2025 – Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of co |
|
| January 7, 2025 |
EX-99.2 Copyright © 2025 Stryker This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements, including statements regarding the anticipated benefits to Str |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Stryker Corporation (Exact name of Registrant as Specified in Its Charter) Michigan 001-13149 38-1239739 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Offeror) A wholly owned subsidiary of Stryker Corporation (Parent of Offeror) Common Stock, par value $0.001 per share (Title of Class of |
|
| January 7, 2025 |
EX-99.4 Exhibit 99.4 Social Media Posts Inari LinkedIn 1.6.25 Inari X / Twitter 1.6.25 Inari Facebook 1.6.25 Inari Instagram 1.6.25 Forward-Looking Statements This communication may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “sho |
|
| January 7, 2025 |
EX-99.3 Exhibit 99.3 Dear Valued Customer, Today, we announced that Inari Medical has entered into a definitive agreement to be acquired by Stryker. You can read the press release announcing the transaction here. This is an exciting development that will greatly benefit patients, physicians, and hospitals. What will not change is the commitment to our products, clinical trials, physician support a |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 6, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and between STRYKER CORPORATION and INARI MEDICAL, INC. Dated as of January 6, 2025 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER AND MERGER Section 1.1 The Offer 2 Section 1.2 Company Actions 4 Section 1.3 The Merger 5 Section 1.4 Closing 6 Section 1.5 Effective Time 6 Section 1.6 Effects of the Merger 6 Section 1.7 Organizational Documents of the Survivin |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) INARI MEDICAL, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number of |
|
| January 6, 2025 |
Exhibit 99.1 Source: Stryker Corporation January 06, 2025 16:08 ET Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the iss |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Inari Medical, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) un |
|
| November 8, 2024 |
NARI / Inari Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 7, 2024 |
EX-99.1 2 d867443dex991.htm EX-99.1 Exhibit 99.1 Joint Filer Agreement The undersigned hereby agree and acknowledge that the statement containing the information required by Schedule 13G, to which this agreement is attached as an exhibit, is filed on behalf of each of them, and any amendments or supplements to the Schedule 13G shall also be filed on behalf of each of them. Dated: 11/7/2024 CVF, LL |
|
| November 7, 2024 |
NARI / Inari Medical, Inc. / CVF, LLC - SC 13G/A Passive Investment SC 13G/A 1 d867443dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| October 28, 2024 |
effective October 1, 2024, by and between Inari Medical, Inc. and Kevin Strange Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2024, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Kevin Strange (the “Executive”). WHEREAS, the Executive is currently employed as the Senior Vice President of Finance, Accounting, Strategy and Business Development of the Company and, effecti |
|
| October 28, 2024 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INARI MEDICAL, INC. (a Delaware corporation) (amended and restated as of October 25, 2024) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETINGS 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A |
|
| October 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| October 28, 2024 |
Inari Medical Reports Third Quarter 2024 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2024 Financial Results IRVINE, CALIFORNIA – October 28, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Fin |
|
| July 30, 2024 |
Exhibit 99.1 Inari Medical Announces Chief Financial Officer Retirement and Succession Plan Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 IRVINE, CALIFORNIA – July 30, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| July 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 30, 2024 |
Inari Medical Reports Second Quarter 2024 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2024 Financial Results IRVINE, CALIFORNIA – July 30, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024. Second Quarter Financia |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 6001 Oak Canyon, Suite 100 92618 Irvine, California (Zip Code) |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2024 |
Inari Medical Reports First Quarter 2024 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2024 Financial Results IRVINE, CALIFORNIA – April 30, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024. First Quarter Financial |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 3, 2024 |
NARI / Inari Medical, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INARI MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45332Y109 (CUSIP Number) MARCH 27, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| March 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| February 29, 2024 |
INARI MEDICAL, INC. CLAWBACK POLICY Exhibit 97.1 INARI MEDICAL, INC. CLAWBACK POLICY Inari Medical, Inc. (the “Company”) has adopted this clawback policy (the “Policy”) to address the requirements of the clawback rules found in 17 C.F.R. §240.10D-1 and the related listing rules of The Nasdaq Stock Market, LLC (“Nasdaq” or the “Exchange”). This Policy shall be interpreted to comply with such clawback rules and, to the extent this Pol |
|
| February 29, 2024 |
Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Latin America, Inc. Delaware Inari Medical Australia Pty. Ltd. Australia Inari Medical Distribuicao de Dispositivos Medicos Ltda. Brazil Inari Medical Canada, Inc. Canada Inari Medical Chile SpA Chile Inari Medical Costa Rica, S.A. Costa Rica Inari Med |
|
| February 29, 2024 |
1, by and between Inari Medical, Inc. and Oak Canyon Creek LLC Exhibit 10.16 SECOND AMENDMENT TO LEASE I.PARTIES AND DATE. This Second Amendment to Lease (“Amendment”) dated July 16, 2021, by and between OAK CANYON CREEK LLC, a Delaware limited liability company (“Landlord”), and INARI MEDICAL, INC., a Delaware corporation (“Tenant”). II.RECITALS. On October 7, 2020, Landlord and Tenant entered into a lease for space in a building located at 6001 Oak Canyon, |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inari Medical, Inc. |
|
| February 29, 2024 |
Exhibit 10.28 SEVENTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT This SEVENTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of January 24, 2024, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDICAL LATIN AMERICA, INC., a Del |
|
| February 29, 2024 |
on-Employee Director Compensation Program Exhibit 10.29 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of January 1, 2024) Eligible Directors (as defined below) on the board of directors (the “Board”) of Inari Medical, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to t |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-3929 |
|
| February 29, 2024 |
Form of Performance Based Restricted Stock Unit Award Agreement Exhibit 10.30 INARI MEDICAL, INC. 2020 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE Inari Medical, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Performance-Based Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the |
|
| February 28, 2024 |
Inari Medical Reports Fourth Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports Fourth Quarter 2023 Financial Results IRVINE, CALIFORNIA – February 28, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023. F |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0789exhibit99.htm JOING FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| February 14, 2024 |
NARI / Inari Medical, Inc. / Point72 Asset Management, L.P. - INARI MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 13, 2024 |
NARI / Inari Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01172-inarimedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Inari Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 45332Y109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate |
|
| February 8, 2024 |
NARI / Inari Medical, Inc. / MILDER DONALD B - SC 13G/A Passive Investment SC 13G/A 1 d763639dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value |
|
| February 8, 2024 |
NARI / Inari Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 31, 2024 |
Exhibit 99.1 LIMFLOW CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2022 AND AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 LIMFLOW S.A. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AUDITED CONSOLIDATED FINANCIAL STATEMENTS: Page Independent Auditor's Report 2 Consolidated Balance Sheets 4 Consolidated Statements of Operations and Comprehensive Loss 6 Consolidate |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 31, 2024 |
Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Information Introduction On November 15, 2023 (the “Closing Date”), Inari Medical, Inc (“Inari” or the “Company”) consummated the previously announced acquisition of LimFlow S.A (“LimFlow” or the “Seller”). On November 1, 2023, the Company announced that it entered into a share purchase agreement (the “Purchase Agreement”) to acquire Li |
|
| January 9, 2024 |
Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance Exhibit 99.1 Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance IRVINE, CALIFORNIA – January 9th, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and estab |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 15, 2023 |
Inari Medical Closes Acquisition of LimFlow Exhibit 99.1 Inari Medical Closes Acquisition of LimFlow IRVINE, Calif., November 15, 2023 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients w |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 2, 2023 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 2, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow Announces Q3 2023 Financial Results Inari to Host Conference Call Today at 1:30 P.M. PT / 4:30 P.M. ET IRVINE, Calif., November 1, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of pati |
|
| November 2, 2023 |
Cindy LimFlow Patient Inari Medical Investor Update November 2023 Exhibit 99.2 This presentation (together with any other statements or information that we may make in connection therewith) may contain are forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including anticipated closing of the LimFlow Acquisition (as defined below), |
|
| November 2, 2023 |
Exhibit 10.1 Execution Version SIXTH AMENDMENT AND LIMITED CONSENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This SIXTH AMENDMENT AND LIMITED CONSENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of November 1, 2023, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDIC |
|
| November 2, 2023 |
Exhibit 2.1 EXECUTION VERSION SHARE PURCHASE AGREEMENT by and among LimFlow S.A., the Sellers, Shareholder Representative Services LLC, solely in its capacity as the Seller Representative, Inari Medical, Inc., solely for the purposes of Section 13.16, and Lombardi Sub, LLC DATED AS OF OCTOBER 31, 2023 Table of Contents CONTENTS Page ARTICLE I PURCHASE AND SALE 2 1.1 Purchase and Sale 2 1.2 Purchas |
|
| November 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 1, 2023 |
Inari Medical Reports Third Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2023 Financial Results IRVINE, CALIFORNIA – November 1, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2023. Third Quarter Fin |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 22, 2023 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of September 18, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Mitchell Hill (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the Executive, date |
|
| September 22, 2023 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of September 18, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Andrew Hykes (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the Executive, dated |
|
| September 22, 2023 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of September 18, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Thomas Tu, M.D. (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the Executive, da |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| August 2, 2023 |
Inari Medical Reports Second Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2023 Financial Results IRVINE, CALIFORNIA – August 2, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2023. Second Quarter Financi |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 6001 Oak Canyon, Suite 100 92618 Irvine, California (Zip Code) |
|
| May 19, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 3, 2023 |
Inari Medical Reports First Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2023 Financial Results IRVINE, CALIFORNIA – May 3, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023. First Quarter Financial an |
|
| May 3, 2023 |
Amended and Restated Non-Employee Director Compensation Program Exhibit 10.2 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of May 1, 2023) Eligible Directors (as defined below) on the board of directors (the “Board”) of Inari Medical, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to time, |
|
| May 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 3, 2023 |
dated February 14, 2023, by and between Inari Medical Inc. and Oak Canyon Creek LLC Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. (***) INDICATES THAT INFORMATION HAS BEEN REDACTED. THIRD AMENDMENT TO LEASE I.PARTIES AND DATE. This Third Amendment to Lease (“Amendment”) dated February 14, 2023, by and between OAK CANYON CREEK LLC, a Delaware limited lia |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| April 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| April 6, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| February 27, 2023 |
Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results IRVINE, CALIFORNIA – February 27, 2023 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended Decemb |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-392 |
|
| February 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inari Medical, Inc. |
|
| February 27, 2023 |
Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Europe GmbH Switzerland Inari Medical Asia PTE. LTD. Singapore Inari Medical Canada, Inc. Canada Inari Medical Latin America, Inc. Delaware Inari Medical Australia Pty. Ltd. Australia Inari Medical Distribuicao de Dispositivos Medicos Ltda. Brazil Inar |
|
| February 27, 2023 |
As filed with the Securities and Exchange Commission on February 27, 2023 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No. |
|
| February 27, 2023 |
Exhibit 10.28 FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT This FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of December 16, 2022, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDICAL LATIN AMERICA, INC., a Dela |
|
| February 27, 2023 |
Exhibit 10.29 FIFTH AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This FIFTH AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of February 6, 2023, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDICAL LATIN AMERICA, INC., a Delaware corporation (“IMLA” an |
|
| February 24, 2023 |
NARI / Inari Medical Inc / Point72 Asset Management, L.P. - INARI MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45332Y109 (CUSIP Number) February 22, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 14, 2023 |
EX-99.B 3 d445094dex99b.htm EX-99.B Exhibit 99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited and incorporated by reference to 13G filings made by Macquarie Group Limited and on May 25, 2021. Page 13 of 13 |
|
| February 14, 2023 |
EX-99.A 2 d445094dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). WHEREAS, th |
|
| February 14, 2023 |
NARI / Inari Medical Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Inari Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 14, 2023 |
NARI / Inari Medical Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d445094dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45332Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 13, 2023 |
NARI / Inari Medical Inc / MILDER DONALD B - SC 13G/A Passive Investment SC 13G/A 1 d446366dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value |
|
| February 13, 2023 |
NARI / Inari Medical Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 10, 2023 |
NARI / Inari Medical Inc / CVF, LLC - SC 13G/A Passive Investment SC 13G/A 1 d232018dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 9, 2023 |
NARI / Inari Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Inari Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 45332Y109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 6, 2023 |
NARI / Inari Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 27, 2023 |
EX-10.1 2 nari-ex101.htm EX-10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of January 1, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Andrew Hykes (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the |
|
| January 10, 2023 |
Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance Exhibit 99.1 Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance IRVINE, CALIFORNIA – January 10, 2023 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2022 revenue and provid |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 19, 2022 |
Exhibit 10.1 FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT This FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this ?Amendment?), dated as of December 16, 2022, is by and among INARI MEDICAL, INC., a Delaware corporation (the ?Borrower?), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the ?IMI?), INARI MEDICAL LATIN AMERICA, INC., a Delaw |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 2, 2022 |
Inari Medical Reports Third Quarter 2022 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2022 Financial Results IRVINE, CALIFORNIA ? November 2, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2022. Third Quarter Rev |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| September 20, 2022 |
Exhibit 99.1 2022 Inari Medical Investor Day Sandy | Boynton Beach, FL Financial Information Unless otherwise indicated, all financial and operational information included herein is as of June 30, 2022. Indications for Use and Publication References Indications for Use and relevant labeling information for all Inari products included in this presentation are included in the appendix. References to |
|
| September 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 3, 2022 |
Inari Medical Reports Second Quarter 2022 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2022 Financial Results IRVINE, CALIFORNIA – August 3, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2022. Second Quarter Revenue |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| August 3, 2022 |
Third Amendment and Joinder to the Loan, Guaranty and Security Agreement, dated as of July 21, 2022 Exhibit 10.1 THIRD AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This THIRD AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of July 21, 2022, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “Guarantor”), each of the lenders signatory hereto (the “Lenders”), and BANK OF |
|
| August 3, 2022 |
Inari Medical Announces Leadership Succession Plan Exhibit 99.1 Inari Medical Announces Leadership Succession Plan Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023 IRVINE, Calif., August 3, 2022 ? Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that Chief Operating Officer Drew Hy |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| May 4, 2022 |
Inari Medical Reports First Quarter 2022 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2022 Financial Results IRVINE, CALIFORNIA ? May 4, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022. First Quarter Revenue and |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ? 240. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ? 240. |
|
| March 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Inari Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation) (Commission File |
|
| March 15, 2022 |
EX-1.1 2 d322159dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION INARI MEDICAL, INC. (a Delaware corporation) 2,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 10, 2022 INARI MEDICAL, INC. (a Delaware corporation) 2,000,000 Shares of Common Stock UNDERWRITING AGREEMENT March 10, 2022 BofA Securities, Inc. Morgan Stanley & Co. LLC as Representatives of the several Underwriters c/o |
|
| March 11, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables 424(b)(5) (Form Type) Inari Medical, Inc. |
|
| March 11, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261882 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 2,000,000 Shares Common Stock We are offering 2,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?NARI.? On March 9, 2022, the last reported sale price of our common stock on the Nasdaq Global |
|
| March 10, 2022 |
Subject to Completion Preliminary Prospectus Supplement dated March 10, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261882 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are n |
|
| March 1, 2022 |
Inari Medical Appoints Robert Warner to Board of Directors Exhibit 99.1 Inari Medical Appoints Robert Warner to Board of Directors IRVINE, CALIFORNIA ? March 1, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 23, 2022 |
Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Europe GmbH Switzerland Inari Medical Asia PTE. LTD. Singapore Inari Medical Canada, Inc. Canada |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39293 Inari Medical, |
|
| February 23, 2022 |
Exhibit 4.6 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock of Inari Medical, Inc. (the ?Company,? ?we,? ?us,? and ?our?) and certain provisions of our amended and restated certificate of incorporation, as amended from time to time (the ?amended and restated certificate of incorporation?) and amended and restated bylaws, as amended from time to time (the ?amended and re |
|
| February 23, 2022 |
Exhibit 10.25 INARI MEDICAL, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE NON-EMPLOYEE DIRECTOR Inari Medical, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Ina |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inari Medical, Inc. |
|
| February 23, 2022 |
Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results IRVINE, CALIFORNIA ? February 23, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended Decembe |
|
| February 23, 2022 |
Second Amendment to Loan, Guaranty and Security Agreement, dated as of November 8, 2021 Exhibit 10.24 SECOND AMENDMENT AND LIMITED WAIVER TO LOAN, GUARANTY AND SECURITY AGREEMENT This SECOND AMENDMENT AND LIMITED WAIVER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this ?Amendment?), dated as of November 8, 2021, is by and among INARI MEDICAL, INC., a Delaware corporation (the ?Borrower?), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the ?Guarantor?), each of the lenders si |
|
| February 23, 2022 |
As filed with the Securities and Exchange Commission on February 23, 2022 As filed with the Securities and Exchange Commission on February 23, 2022 Registration No. |
|
| February 23, 2022 |
Amended and Restated Non-Employee Director Compensation Program Exhibit 10.14 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of January 1, 2022) Eligible Directors (as defined below) on the board of directors (the ?Board?) of Inari Medical, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to t |
|
| February 14, 2022 |
NARI / Inari Medical Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 14, 2022 |
NARI / Inari Medical Inc / MACQUARIE GROUP LTD - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Inari Medical Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 11, 2022 |
NARI / Inari Medical Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 11, 2022 |
NARI / Inari Medical Inc / MILDER DONALD B - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 10, 2022 |
NARI / Inari Medical Inc / CVF, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 10, 2022 |
NARI / Inari Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Inari Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 45332Y109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule |
|
| February 4, 2022 |
NARI / Inari Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 27, 2022 |
NARI / Inari Medical Inc / US VENTURE PARTNERS X LP - SC 13G/A Passive Investment SC 13G/A 1 tm224259d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 10, 2022 |
Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue Exhibit 99.1 Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue IRVINE, CALIFORNIA ? January 10, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue. Preliminary Fourth Quar |
|
| December 23, 2021 |
Exhibit 4.4 Inari Medical, Inc. INDENTURE Dated as of , 20 [TRUSTEE] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ |
|
| December 23, 2021 |
As filed with the Securities and Exchange Commission on December 23, 2021 Table of Contents As filed with the Securities and Exchange Commission on December 23, 2021 Registration No. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| November 9, 2021 |
Inari Medical Reports Third Quarter 2021 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2021 Financial Results IRVINE, CALIFORNIA ? November 9, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, 2021. Third Quart |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 01, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 1, 2021 |
Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors Exhibit 99.1 Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors IRVINE, CALIFORNIA ? October 1, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors. Mr. Me |
|
| September 8, 2021 |
NARI / Inari Medical Inc / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat |
|
| September 8, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the time |
|
| August 27, 2021 |
NARI / Inari Medical Inc / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperatieve Gild |
|
| August 27, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the time |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 10, 2021 |
Inari Medical Reports Second Quarter 2021 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2021 Financial Results IRVINE, CALIFORNIA ? August 10, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021. |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 22, 2021 |
Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors Exhibit 99.1 Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors IRVINE, CALIFORNIA - June 22, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Ms. Rebecca Chambers to its board |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization) ( |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation or organization) (C |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization) ( |
|
| May 11, 2021 |
Inari Medical Reports First Quarter 2021 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2021 Financial Results IRVINE, Calif., May 11, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its first quarter ended March 31, 2021. First Qu |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| April 27, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperatieve Gild |
|
| April 27, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization) |
|
| March 31, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 30, 2021, is by and among INARI MEDICAL, INC., a Delaware corporation (the ?Borrower?), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the ?Guarantor?), each of the lenders signatory hereto (the ?Lenders?), and BANK OF |
|
| March 17, 2021 |
OMB APPROVAL OMB Number: 3235-0101 Expires: July 31, 2023 Estimated average burden hours per response 1. |
|
| March 16, 2021 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 10, 2021 Registration No. |
|
| March 9, 2021 |
Amended and Restated Non-Employee Director Compensation Program Exhibit 10.14 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of January 1, 2021) Eligible Directors (as defined below) on the board of directors (the ?Board?) of Inari Medical, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to t |
|
| March 9, 2021 |
EX-10.13 3 nari-ex1013763.htm EX-10.13 Exhibit 10.13 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of September 1, 2020, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Thomas Tu, M.D. (the “Executive”). WHEREAS, the Company desires to continue the employment of the Executive and the Company and the Executive desire to en |
|
| March 9, 2021 |
Exhibit 10.18 FIRST AMENDMENT TO LEASE I.PARTIES AND DATE. This First Amendment to Lease (?Amendment?) dated March 3, 2021, is by and between OAK CANYON CREEK LLC, a Delaware limited liability company (?Landlord?), and INARI MEDICAL, INC., a Delaware corporation (?Tenant?). II.RECITALS. On October 7, 2020, Landlord and Tenant entered into a lease (?Lease?) for space in a building located at 6001 O |
|
| March 9, 2021 |
Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 2 nari-ex9916.htm EX-99.1 Exhibit 99.1 Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results IRVINE, Calif., March 9, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results fo |
|
| March 9, 2021 |
Subsidiaries of the registrant EX-21.1 7 nari-ex211764.htm EX-21.1 Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Europe GmbH Switzerland |
|
| March 9, 2021 |
EX-10.17 5 nari-ex1017911.htm EX-10.17 Exhibit 10.17 FIRST AMENDMENT TO LEASE TERMINATION AGREEMENT I. PARTIES AND DATE. This First Amendment to Lease Termination Agreement (“Amendment”) dated February 3, 2021, is by and between BAKE TECHNOLOGY PARK LLC, a Delaware limited liability company (“Landlord”), and INARI MEDICAL, INC., a Delaware corporation (“Tenant”). II. RECITALS. On March 6, 2019, La |
|
| March 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization) |
|
| March 9, 2021 |
Form of Restricted Stock Unit Award Agreement pursuant to 2020 Incentive Award Plan – International Exhibit 10.8 INARI MEDICAL, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice NON-US PARTICIPANTS Inari Medical, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Inari |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39293 Inari Medical, |
|
| February 9, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Sta |
|
| February 8, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securi |
|
| February 5, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 13, 2021 |
Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue EX-99.1 2 nari-ex9916.htm EX-99.1 Exhibit 99.1 Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue IRVINE, Calif., Jan 13, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quar |
|
| January 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizatio |
|
| December 23, 2020 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat |
|
| December 4, 2020 |
NARI / Inari Medical, Inc. / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat |
|
| November 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizati |
|
| November 12, 2020 |
Inari Medical Reports Third Quarter 2020 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2020 Financial Results IRVINE, CALIFORNIA – November 12, 2020 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, |
|
| November 12, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizati |
|
| November 12, 2020 |
Exhibit 10.2 LEASE TERMINATION AGREEMENT I. PARTIES AND DATE. THIS LEASE TERMINATION AGREEMENT ("Agreement") is made and entered into as of October 7, 2020 , by and between BAKE TECHNOLOGY PARK LLC a Delaware limited liability company ("Landlord"), and INARI MEDICAL, INC., a Delaware corporation (?Tenant?). II. RECITALS. On March 6, 2019, Landlord and Tenant entered into a lease (?Lease?) for spac |
|
| November 12, 2020 |
Amended and Restated 2020 Employee Stock Purchase Plan Exhibit 10.3 inari medical, inc. AMENDED AND RESTATED 2020 EMPLOYEE STOCK PURCHASE PLAN Article I. PURPOSE The purposes of this Inari Medical, Inc. Amended and Restated 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of Inari Medical, Inc., a Delaware corporation (the ?Company?), and the other Participating Compani |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| November 12, 2020 |
Exhibit 10.1 LEASE BETWEEN OAK CANYON CREEK LLC AND INARI MEDICAL, INC. LEASE THIS LEASE is made as of October 7, 2020, by and between OAK CANYON CREEK LLC, a Delaware limited liability company, hereafter called ?Landlord,? and INARI MEDICAL, INC., a Delaware corporation, hereafter called ?Tenant.? ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this Lease to the ?Basic Lease Provisions? shall |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizatio |
|
| October 13, 2020 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization |
|
| September 17, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizat |
|
| September 17, 2020 |
Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer Exhibit 99.1 Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer IRVINE, CALIFORNIA – September 17, 2020 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Opera |
|
| September 11, 2020 |
Exhibit 10.1 LOAN, GUARANTY AND SECURITY AGREEMENT Dated as of September 4, 2020 INARI MEDICAL, INC., and CERTAIN SUBSIDIARIES FROM TIME TO TIME JOINED HERETO, as Borrowers, INARI MEDICAL INTERNATIONAL, INC., and CERTAIN SUBSIDIARIES FROM TIME TO TIME JOINED HERETO, as Guarantors, BANK OF AMERICA, N.A., as Agent, Sole Lead Arranger and Sole Bookrunner 1333152378 Table of Contents Page Section 1. D |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizati |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc. |
|
| August 11, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization |
